{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:57:06Z","timestamp":1789577826327,"version":"build-2803163510"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.bioorg.2023.106735","type":"journal-article","created":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T20:59:38Z","timestamp":1689368378000},"page":"106735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Novel quinoxaline-based VEGFR-2 inhibitors to halt angiogenesis"],"prefix":"10.1016","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3915-9786","authenticated-orcid":false,"given":"Magda M.F.","family":"Ismail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taghreed Z.","family":"Shawer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabab S.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha M.","family":"Allam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousry A.","family":"Ammar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2023.106735_b0005","doi-asserted-by":"crossref","unstructured":"Cell Communication and Signaling (2022) 20-49. https:\/\/doi.org\/10.1186\/s12964-022-00838-y.","DOI":"10.1186\/s12964-022-00838-y"},{"key":"10.1016\/j.bioorg.2023.106735_b0010","first-page":"350","article-title":"Medicinal attributes of thienopyrimidine based scaffold targeting tyrosine kinases and their potential anticancer activities","author":"Ghith","year":"2017","journal-title":"Archiv der Pharmazie"},{"key":"10.1016\/j.bioorg.2023.106735_b0015","doi-asserted-by":"crossref","unstructured":"M. M. Alanazi,I. H. Eissa,N. A. Alsaif,A. J. Obaidullah,W. A. Alanazi,A. F. Alasmari,H. Albassam,H. Elkady,andA. Elwan Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers, J. Enzyme Inhib. Med. Chem.36 (1) (2021) 1760\u20131782.doi:10.1080\/14756366.2021.1956488.","DOI":"10.1080\/14756366.2021.1956488"},{"key":"10.1016\/j.bioorg.2023.106735_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10456-017-9583-4","article-title":"Mechanisms of angiogenesis in microbe-regulated inflammatory and neoplastic conditions","volume":"21","author":"Sajib","year":"2018","journal-title":"Angiogenesis"},{"key":"10.1016\/j.bioorg.2023.106735_b0025","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.3390\/molecules26071952","article-title":"Synthesis and rational design of new appended 1,2,3-triazole-uracil ensembles as promising anti-tumor agents via in silico VEGFR-2 transferase inhibition","volume":"26","author":"Reddy","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2023.106735_b0030","doi-asserted-by":"crossref","unstructured":"S. Rampogu, A. Baek, A. Zeb, K.W. Lee, Exploration for novel inhibitors showing back-to-front approach against VEGFR-2kinase domain (4AG8) employing molecular docking mechanism and molecular dynamics simulations, BMC Cancer 18 (2018) 1\u201321.[CrossRef].","DOI":"10.1186\/s12885-018-4050-1"},{"key":"10.1016\/j.bioorg.2023.106735_b0035","doi-asserted-by":"crossref","unstructured":"J. Li, N. Zhou, K. Luo, W. Zhang, X. Li, C. Wu, J. Bao, In Silico discovery of potential VEGFR-2 inhibitors from natural derivatives for anti-angiogenesis therapy, Int. J. Mol. Sci. 15 (2014) 15994\u201316011. [CrossRef].","DOI":"10.3390\/ijms150915994"},{"key":"10.1016\/j.bioorg.2023.106735_b0040","article-title":"Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors","volume":"104","author":"Saleh","year":"2020","journal-title":"Bio. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2023.106735_b0045","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/1947601911423031","article-title":"Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis, a crucial target for anti- and pro-angiogenic therapies","volume":"2","author":"Shibuya","year":"2011","journal-title":"Genes Cancer"},{"issue":"7","key":"10.1016\/j.bioorg.2023.106735_b0050","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ctrv.2012.04.006","article-title":"Role of angiogenesis in the pathogenesis of cancer","volume":"38","author":"Hoff","year":"2012","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bioorg.2023.106735_b0055","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/jcp.2003.012963","article-title":"Expression of vascular endothelial growth factor, hypoxia inducible factor 1\u03b1, and carbonic anhydrase IX in human","volume":"57","author":"Jubb","year":"2004","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.bioorg.2023.106735_b0060","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/jnci\/89.2.139","article-title":"Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma","volume":"89","author":"Gasparini","year":"1997","journal-title":"J. Nat. Cancer Inst"},{"key":"10.1016\/j.bioorg.2023.106735_b0065","doi-asserted-by":"crossref","unstructured":"N. R. Smith, D. Baker, N. H. James, K. Ratcliffe, M. Jenkins, S. E. Ashton, G. Sproat, R. Swann, N. Gray, A. Ryan, J. M. Jurgensmeier, C. Womack, Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers, Clin. Cancer Res. 16 (14) (2010) 3548\u20133561.","DOI":"10.1158\/1078-0432.CCR-09-2797"},{"key":"10.1016\/j.bioorg.2023.106735_b0070","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.3390\/molecules24061175","article-title":"Design and synthesis of new quinoxaline derivatives as anticancer agents and apoptotic inducers","volume":"24","author":"El Newahie","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2023.106735_b0075","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/ardp.201500468","article-title":"Quinoxaline-based scaffolds targeting tyrosine kinases and their potential anticancer activity","volume":"349","author":"El Newahie","year":"2016","journal-title":"Arch. Pharm. Chem. Life Sci."},{"key":"10.1016\/j.bioorg.2023.106735_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112752","article-title":"Novel 2-indolinone thiazole hybrids as sunitinib analogues: design, synthesis, and potent VEGFR-2 inhibition with potential anti-renal cancer activity","volume":"208","author":"Mahmoud","year":"2020","journal-title":"Euro. J. of Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106735_b0085","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1023\/A:1021528628524","article-title":"Comparative study of isoflavone, quinoxaline and oxindole families of anti-angiogenic agents","volume":"5","author":"Whatmore","year":"2002","journal-title":"Angiogenesis"},{"key":"10.1016\/j.bioorg.2023.106735_b0090","first-page":"3540","article-title":"Flk-1 as a target for tumor growth inhibition","volume":"56","author":"Strawn","year":"1996","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bioorg.2023.106735_b0095","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1517\/13543776.7.6.571","article-title":"Protein tyrosine kinase inhibitors in cancer treatment","volume":"7","author":"Traxler","year":"1997","journal-title":"Expert Opin. Therapeutic Patents"},{"issue":"7","key":"10.1016\/j.bioorg.2023.106735_b0100","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.3390\/molecules27072047","article-title":"Novel 1,2,3-triazole-coumarin hybrid glycosides and their tetrazolyl analogues: design, anticancer evaluation and molecular docking targeting EGFR, VEGFR-2 and CDK-2","volume":"27","author":"El-Sayed","year":"2022","journal-title":"Mol."},{"issue":"10","key":"10.1016\/j.bioorg.2023.106735_b0105","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1007\/s00044-021-02773-y","article-title":"Synthesis and antiproliferative activity of hybrid thiosemicarbazone derivatives bearing coumarin and d-galactose moieties with EGFR inhibitory activity and molecular docking study","volume":"30","author":"Toan","year":"2021","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.bioorg.2023.106735_b0110","doi-asserted-by":"crossref","unstructured":"E. Y. Ahmed, W. S. Elserwy, M. F. El-Mansy, A. M. Serry, A. M. Salem, A. M. Abdou, B. A. Abdelrahman, K. H. Elsayed, M. R. A. Elaziz, Angiokinase inhibition of VEGFR-2, PDGFR and FGFR and cell growth inhibition in lung cancer: Design, synthesis, biological evaluation and molecular docking of novel azaheterocyclic coumarin derivatives,Bioorg. Med. Chem. Lett.48 (2021) 128258. [Google Scholar] [CrossRef].","DOI":"10.1016\/j.bmcl.2021.128258"},{"key":"10.1016\/j.bioorg.2023.106735_b0115","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bioorg.2018.12.040","article-title":"Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis","volume":"85","author":"Mohamed","year":"2019","journal-title":"Bioorganic Chem."},{"key":"10.1016\/j.bioorg.2023.106735_b0120","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.bioorg.2019.01.026","article-title":"New thiazol-hydrazono-coumarin hybrids targeting human cervical cancer cells: synthesis, CDK2 inhibition, QSAR and molecular docking studies","volume":"86","author":"Abd El-Karim","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2023.106735_b0125","first-page":"434","article-title":"Synthesis, antitumor activity, pharmacophore modeling and QSAR studies of novel pyrazoles and pyrazolo [1, 5-a] pyrimidines against breast adenocarcinoma mcf-7 cell line","volume":"8","author":"Ismail","year":"2016","journal-title":"Int. J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2023.106735_b0130","doi-asserted-by":"crossref","first-page":"2000214","DOI":"10.1002\/ardp.202000214","article-title":"Synthesis of new arylazopyrazoles as apoptosis inducers: candidates to inhibit proliferation of MCF-7 cells","volume":"354","author":"Ismail","year":"2020","journal-title":"Arch. Pharm."},{"issue":"7","key":"10.1016\/j.bioorg.2023.106735_b0135","doi-asserted-by":"crossref","first-page":"948","DOI":"10.2174\/1871520619666190207094610","article-title":"Novel 1,3,4-triaryl pyrazoles: synthesis, QSAR studies and cytotoxicity against breast cancer","volume":"19","author":"Ismail","year":"2019","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106735_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104368","article-title":"Design and synthesis of novel tranilast analogs: docking, antiproliferative evaluation and in-silico screening of TGF\u03b2R1 inhibitors","volume":"105","author":"Ismail","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2023.106735_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104378","article-title":"New cyanopyridine-based scaffold as PIM-1 inhibitors and apoptotic inducers: Synthesis and SARs study","volume":"105","author":"Farrag","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2023.106735_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103481","article-title":"Apoptosis: A target for anticancer therapy with novel cyanopyridines","volume":"94","author":"Ismail","year":"2020","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2023.106735_b0155","doi-asserted-by":"crossref","first-page":"63","DOI":"10.18576\/jpac\/030109","article-title":"Design, synthesis and QSAR studies of novel 1,3,4-triarylpyrazoles as anti-breast cancer agents","volume":"3","author":"Farrag","year":"2017","journal-title":"J. Pharm. Appl. Chem."},{"key":"10.1016\/j.bioorg.2023.106735_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jhet.4064","article-title":"Synthesis, anticancer screening, and in silico ADME prediction of novel 2-pyridones as Pim inhibitors","volume":"57","author":"Ismail","year":"2020","journal-title":"J. Heterocycl. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2023.106735_b0165","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1016\/j.ejmech.2010.09.002","article-title":"Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors","volume":"45","author":"Lee","year":"2010","journal-title":"Eur. J. Med. Chem."},{"issue":"19","key":"10.1016\/j.bioorg.2023.106735_b0170","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1016\/j.bmc.2015.08.010","article-title":"Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno [3, 2-b] pyridin-7-ylthio) phenyl] ureas: Discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors","volume":"23","author":"Machado","year":"2015","journal-title":"Bioorg. med. Chem."},{"key":"10.1016\/j.bioorg.2023.106735_b0175","doi-asserted-by":"crossref","first-page":"5738","DOI":"10.1016\/j.bmc.2010.05.063","article-title":"The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec VR, Nexavar VR, and BIRB-796","volume":"18","author":"Dietrich","year":"2010","journal-title":"Bioorg. Med. Chem."},{"issue":"17","key":"10.1016\/j.bioorg.2023.106735_b0180","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.2174\/092986707781058805","article-title":"Molecular hybridization: a useful tool in the design of new drug prototypes","volume":"14","author":"Viegas-Junior","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106735_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.130317","article-title":"Design, synthesis, antiproliferative evaluation, and molecular docking study of new quinoxaline derivatives as apoptotic inducers and EGFR inhibitors","volume":"1236","author":"Fayed","year":"2021","journal-title":"J. Mol. Struct."},{"issue":"516","key":"10.1016\/j.bioorg.2023.106735_b0190","first-page":"151","article-title":"3- Ethoxycarbonylmethylenequinoxalin-2-one in heterocyclic Synthesis. Part 1: synthesis of new substituted and condensed quinoxalines","volume":"62","author":"Ammar","year":"2005","journal-title":"Afinidad"},{"key":"10.1016\/j.bioorg.2023.106735_b0195","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.toxlet.2018.04.008","article-title":"Fingolimod interrupts the cross talk between estrogen metabolism and sphingolipid metabolism within prostate cancer cells","volume":"291","author":"Allam","year":"2018","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.bioorg.2023.106735_b0200","doi-asserted-by":"crossref","first-page":"36855","DOI":"10.1038\/srep36855","article-title":"Didox and resveratrol sensitize colorectal cancer cells to doxorubicin via activating apoptosis and ameliorating P-glycoprotein activity","volume":"6","author":"Khaleel","year":"2016","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.bioorg.2023.106735_b0205","article-title":"Comparative effect of tyrosine kinase inhibitors in human cancer cell lines","volume":"1","author":"Shindikar","year":"2016","journal-title":"J. Pharma. Clin. Res."},{"issue":"6","key":"10.1016\/j.bioorg.2023.106735_b0210","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3390\/molecules22060913","article-title":"Synthesis and evaluation of novel 2-pyrrolidone-fused (2-oxoindolin-3-ylidene) methylpyrrole derivatives as potential multi-target tyrosine kinase receptor inhibitors","volume":"22","author":"Yang","year":"2017","journal-title":"Mol."},{"issue":"11","key":"10.1016\/j.bioorg.2023.106735_b0215","first-page":"1416","article-title":"Design, synthesis, molecular modeling, and anticancer evaluation of new VEGFR-2 inhibitors based on the indolin-2-one scaffold","volume":"15","author":"Abdelgawad","year":"2022","journal-title":"Pharma"},{"key":"10.1016\/j.bioorg.2023.106735_b0220","unstructured":"VEGFR-2 (KDR) kinase assay kit catalog, 40325, info@bpsbioscience.com, www.bpsbioscience.com."},{"key":"10.1016\/j.bioorg.2023.106735_b0225","doi-asserted-by":"crossref","first-page":"e435","DOI":"10.1038\/emm.2017.248","article-title":"Rab25 augments cancer cell invasiveness through a \u03b21 integrin\/EGFR\/VEGF-A\/Snail signaling axis and expression of fascin","volume":"50","author":"Jeong","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bioorg.2023.106735_b0230","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3390\/healthcare9070911","article-title":"Modeling and predicting the cell migration properties from scratch wound healing assay on cisplatin-resistant ovarian cancer cell lines using artificial neural network","volume":"9","author":"Bahar","year":"2021","journal-title":"Healthcare"},{"key":"10.1016\/j.bioorg.2023.106735_b0235","doi-asserted-by":"crossref","first-page":"11674","DOI":"10.1038\/s41598-018-30046-z","article-title":"Thymoquinone synergizes gemcitabine anti-breast cancer activity via modulating its apoptotic and autophagic activities","volume":"8","author":"Bashmail","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2023.106735_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112835","article-title":"The influence of antioxidant dietary-derived polyphenolic combination on breast cancer: molecular study","volume":"149","author":"Alqarni","year":"2022","journal-title":"Biomed. Pharmacother"},{"issue":"16","key":"10.1016\/j.bioorg.2023.106735_b0245","doi-asserted-by":"crossref","first-page":"6040","DOI":"10.1016\/j.bmc.2009.06.069","article-title":"Design, synthesis, and discovery of novel non-peptide inhibitor of Caspase-3 using ligand based and structure based virtual screening approach","volume":"17","author":"Jhansi Lakshmi","year":"2009","journal-title":"Bioorg. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2023.106735_b0250","first-page":"a001883","article-title":"Tumor suppressive functions of p53, cold spring harb perspect","volume":"1","author":"Zilfou","year":"2009","journal-title":"Biol"},{"issue":"1","key":"10.1016\/j.bioorg.2023.106735_b0255","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Antoine","year":"2017","journal-title":"Sci. Rep."},{"issue":"1-3","key":"10.1016\/j.bioorg.2023.106735_b0260","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"12","key":"10.1016\/j.bioorg.2023.106735_b0265","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2023.106735_b0270","doi-asserted-by":"crossref","first-page":"5360","DOI":"10.3390\/molecules20045360","article-title":"Synthesis, antiproliferative activity and molecular properties predictions of galloyl derivatives","volume":"20","author":"Maximo da Silva","year":"2015","journal-title":"Mol."},{"issue":"1","key":"10.1016\/j.bioorg.2023.106735_b0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-018-4050-1","article-title":"Exploration for novel inhibitors showing back-to-front approach against VEGFR-2 kinase domain (4AG8) employing molecular docking mechanism and molecular dynamics simulations","volume":"18","author":"Rampogu","year":"2018","journal-title":"BMC cancer"},{"issue":"1","key":"10.1016\/j.bioorg.2023.106735_b0280","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/14756366.2021.2017911","article-title":"Synthesis, biological evaluation, and molecular docking of new series of antitumor and apoptosis inducers designed as VEGFR-2 inhibitors","volume":"37","author":"Abdallah","year":"2022","journal-title":"J. Enz. Inhib. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206823003966?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206823003966?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:56:07Z","timestamp":1758617767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206823003966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":56,"alternative-id":["S0045206823003966"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2023.106735","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel quinoxaline-based VEGFR-2 inhibitors to halt angiogenesis","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2023.106735","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106735"}}